Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 163

Similar articles for PubMed (Select 23728498)

1.

Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry.

Horák P, Skácelová M, Hejduk K, Smržová A, Pavelka K.

Clin Rheumatol. 2013 Oct;32(10):1451-8. doi: 10.1007/s10067-013-2303-6. Epub 2013 Jun 2.

PMID:
23728498
2.

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial.

Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, Li T, Bahrt K, Kelly S, Le Bars M, Genovese MC.

Ann Rheum Dis. 2009 Nov;68(11):1708-14. doi: 10.1136/ard.2008.099218. Epub 2008 Dec 15.

3.

Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.

Genovese MC, Schiff M, Luggen M, Le Bars M, Aranda R, Elegbe A, Dougados M.

J Rheumatol. 2012 Aug;39(8):1546-54. doi: 10.3899/jrheum.111531. Epub 2012 Jul 15.

PMID:
22798265
4.

Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes.

Bathon J, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, Gomez-Reino J, Grassi W, Haraoui B, Shergy W, Park SH, Genant H, Peterfy C, Becker JC, Covucci A, Moniz Reed D, Helfrick R, Westhovens R.

Ann Rheum Dis. 2011 Nov;70(11):1949-56. doi: 10.1136/ard.2010.145268. Epub 2011 Aug 6.

PMID:
21821865
5.

Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry.

Leffers HC, Ostergaard M, Glintborg B, Krogh NS, Foged H, Tarp U, Lorenzen T, Hansen A, Hansen MS, Jacobsen MS, Dreyer L, Hetland ML; all departments of rheumatology in Denmark.

Ann Rheum Dis. 2011 Jul;70(7):1216-22. doi: 10.1136/ard.2010.140129. Epub 2011 May 8.

PMID:
21551512
6.

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors.

Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, Gomez-Reino J, Grassi W, Haraoui B, Shergy W, Park SH, Genant H, Peterfy C, Becker JC, Covucci A, Helfrick R, Bathon J.

Ann Rheum Dis. 2009 Dec;68(12):1870-7. doi: 10.1136/ard.2008.101121. Epub 2009 Jan 5.

7.

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.

Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le Bars M, Dougados M.

Ann Rheum Dis. 2008 Apr;67(4):547-54. Epub 2007 Oct 5.

PMID:
17921185
8.
9.
10.

Disease activity after the discontinuation of biological therapy in inflammatory rheumatic diseases.

Kádár G, Balázs E, Soós B, Laduver A, Keszthelyi P, Szekanecz Z, Kovács L.

Clin Rheumatol. 2014 Mar;33(3):329-33. doi: 10.1007/s10067-014-2508-3. Epub 2014 Feb 5.

PMID:
24497172
11.

Abatacept: a review of its use in the management of rheumatoid arthritis.

Keating GM.

Drugs. 2013 Jul;73(10):1095-119. doi: 10.1007/s40265-013-0080-9. Review.

PMID:
23794171
12.

Effectiveness and safety of abatacept in moderate to severe rheumatoid arthritis.

Cortejoso-Fernández L, Romero-Jiménez MR, Pernía-López MS, Montoro-Álvarez M, Sanjurjo-Sáez M.

J Pharm Pharm Sci. 2012;15(1):46-51.

13.

Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA.

Pavelka K, Forejtová S, Stolfa J, Chroust K, Buresová L, Mann H, Vencovský J.

Clin Exp Rheumatol. 2009 Nov-Dec;27(6):958-63.

PMID:
20149312
14.

Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program.

Weinblatt ME, Moreland LW, Westhovens R, Cohen RB, Kelly SM, Khan N, Pappu R, Delaet I, Luo A, Gujrathi S, Hochberg MC.

J Rheumatol. 2013 Jun;40(6):787-97. doi: 10.3899/jrheum.120906. Epub 2013 Apr 15.

15.

Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.

Wells AF, Westhovens R, Reed DM, Fanti L, Becker JC, Covucci A, Keystone EC.

J Rheumatol. 2011 Nov;38(11):2362-8. doi: 10.3899/jrheum.110054. Epub 2011 Sep 1.

16.

Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study.

Westhovens R, Kremer JM, Moreland LW, Emery P, Russell AS, Li T, Aranda R, Becker JC, Qi K, Dougados M.

J Rheumatol. 2009 Apr;36(4):736-42. doi: 10.3899/jrheum.080813. Epub 2009 Feb 27.

PMID:
19273451
17.

Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.

Sherrer Y.

Curr Med Res Opin. 2008 Aug;24(8):2283-94. doi: 10.1185/03007990802223129. Epub 2008 Jun 27. Review.

PMID:
18590608
18.

Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity.

Takahashi N, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Takagi H, Oguchi T, Miyake H, Kato T, Fukaya N, Ishikawa H, Hayashi M, Tsuboi S, Kanayama Y, Kato D, Funahashi K, Matsubara H, Hattori Y, Hanabayashi M, Hirabara S, Terabe K, Yoshioka Y, Ishiguro N.

Clin Rheumatol. 2014 Jan;33(1):39-47. doi: 10.1007/s10067-013-2392-2. Epub 2013 Sep 22.

19.

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.

Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, Maldonado M, Fleischmann R.

Arthritis Rheum. 2013 Jan;65(1):28-38. doi: 10.1002/art.37711.

20.

Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.

Nüßlein HG, Alten R, Galeazzi M, Lorenz HM, Boumpas D, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Rainer F, Pavelka K, Chartier M, Poncet C, Rauch C, Bars ML.

BMC Musculoskelet Disord. 2014 Jan 11;15:14. doi: 10.1186/1471-2474-15-14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk